Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

February 2014 - FRMC

02/19/2014

Tim Casey

Tim Casey
New Orleans—Patients with untreated multiple myeloma had a cost savings of approximately $29,000 per treatment course if they received bortezomib, cyclophosphamide, and dexamethasone (BCD) compared with a group taking bortezomib,...
New Orleans—Patients with untreated multiple myeloma had a cost savings of approximately $29,000 per treatment course if they received bortezomib, cyclophosphamide, and dexamethasone (BCD) compared with a group taking bortezomib,...
New Orleans—Patients with...
02/19/2014
First Report Managed Care
02/19/2014

Tim Casey

Tim Casey
New Orleans—After at least 24 months of follow-up, heavily pretreated patients with chronic phase or accelerated phase chronic myeloid leukemia (CML) had clinically meaningful and durable responses to omacetaxine, according to a subset...
New Orleans—After at least 24 months of follow-up, heavily pretreated patients with chronic phase or accelerated phase chronic myeloid leukemia (CML) had clinically meaningful and durable responses to omacetaxine, according to a subset...
New Orleans—After at least 24...
02/19/2014
First Report Managed Care
02/19/2014

Tim Casey

Tim Casey
New Orleans—A prespecified subgroup analysis of 2 randomized, phase 3 trials that included patients with acute venous thromboembolism (VTE) found that there was no difference in recurrent VTE or VTE-related mortality if they received...
New Orleans—A prespecified subgroup analysis of 2 randomized, phase 3 trials that included patients with acute venous thromboembolism (VTE) found that there was no difference in recurrent VTE or VTE-related mortality if they received...
New Orleans—A prespecified...
02/19/2014
First Report Managed Care
02/19/2014

Tim Casey

Tim Casey
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective...
02/19/2014
First Report Managed Care
02/19/2014

Tim Casey

Tim Casey
New Orleans—Patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) tolerated a regimen of obinutuzumab and chemotherapy, according to a phase 2, open label, multicenter, single arm trial. The authors mentioned preliminary results...
New Orleans—Patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) tolerated a regimen of obinutuzumab and chemotherapy, according to a phase 2, open label, multicenter, single arm trial. The authors mentioned preliminary results...
New Orleans—Patients newly...
02/19/2014
First Report Managed Care
02/19/2014

Tim Casey

Tim Casey
Patients undergoing allogeneic hematopoietic stem cell transplantation had cognitive impairment on executive function, processing speed, and verbal fluency.
Patients undergoing allogeneic hematopoietic stem cell transplantation had cognitive impairment on executive function, processing speed, and verbal fluency.
Patients undergoing allogeneic...
02/19/2014
First Report Managed Care
02/19/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
  San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...
  San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...
  San Diego—Use of abatacept as...
02/19/2014
First Report Managed Care
02/19/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
San Diego—Long-term outcomes show that golimumab maintains its efficacy for patients with active rheumatoid arthritis (RA) who failed prior biologic therapy with anti-tumor necrosis factor (TNF) therapy.
San Diego—Long-term outcomes show that golimumab maintains its efficacy for patients with active rheumatoid arthritis (RA) who failed prior biologic therapy with anti-tumor necrosis factor (TNF) therapy.
San Diego—Long-term outcomes...
02/19/2014
First Report Managed Care
02/19/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
San Diego—In patients with rheumatoid arthritis (RA), tofacitinib monotherapy significantly inhibits progression of structural damage, improves signs and symptoms of disease, and improves function over 2 years compared to patients treated...
San Diego—In patients with rheumatoid arthritis (RA), tofacitinib monotherapy significantly inhibits progression of structural damage, improves signs and symptoms of disease, and improves function over 2 years compared to patients treated...
San Diego—In patients with...
02/19/2014
First Report Managed Care

Department

Conference Insider
02/19/2014

Mary Beth Nierengarten

Mary Beth Nierengarten
San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.
San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.
San Diego—The efficacy and...
02/19/2014
First Report Managed Care

Advertisement

Advertisement

Advertisement